5 Most Promising Gene Editing Stocks According to Hedge Funds

3. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Investors In Q3 2023: 57

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s treatments seek to target fibrosis, severe pain, high blood pressure, and other ailments. December 2023 was a blockbuster month for the firm as its Sickle Cell Disease treatment secured approval from the FDA to become the first of its kind using gene editing.

By the end of this year’s third quarter, 57 out of the 910 hedge funds surveyed by Insider Monkey had held a stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Jim Simons’ Renaissance Technologies was the largest shareholder as it owns 1.6 million shares that are worth $578 million.

Follow Vertex Pharmaceuticals Inc / Ma (NASDAQ:VRTX)